Lung LCNEC Disease Histology and Prognosis

Author(s):

Martin Dietrich, MD, PhD,Soo-Ryum Yang, MD

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

EP: 1.Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

EP: 2.An Overview of the Molecular Characterization of Lung LCNEC

EP: 3.The Pathological Diagnosis of Lung LCNEC

EP: 4.Biomarker Testing Strategies for Lung LCNEC

EP: 5.Biopsy Best Practices: Diagnosing Lung LCNEC

EP: 6.Lung LCNEC Diagnostic Challenges

EP: 7.A Multidisciplinary Approach to Managing Lung LCNEC

Now Viewing

EP: 8.Lung LCNEC Disease Histology and Prognosis

Given the limited therapeutic options for patients with lung LCNEC, what is your typical treatment approach?
- What patient-specific factors do you consider to guide your first-line treatment selection?
Please share your thoughts on the ASCO 2024 retrospective studies examining first-line systemic treatment outcomes: 1. (Nassar et al, ASCO 2024); 2. (Matteson et al., ASCO 2024)
- What are your key considerations for choosing a second-line treatment strategy?
- How has the tarlatamab approval in SCLC(Ahn et al., NEJM 2023) impacted your treatment approach for patients with LCNEC?